KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to -$318.3 million.

  • Takeda Pharmaceutical's Net Cash Flow rose 8752.09% to -$318.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year decrease of 2632.97%. This contributed to the annual value of $585.0 million for FY2025, which is 1572.4% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Net Cash Flow stood at -$318.3 million for Q4 2025, which was up 8752.09% from $2.2 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Net Cash Flow high stood at $5.0 billion for Q1 2021, and its period low was -$2.9 billion during Q2 2021.
  • Its 5-year average for Net Cash Flow is $313.7 million, with a median of $122.6 million in 2023.
  • The largest annual percentage gain for Takeda Pharmaceutical's Net Cash Flow in the last 5 years was 408195.35% (2024), contrasted with its biggest fall of 131855.4% (2024).
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Net Cash Flow stood at $970.4 million in 2021, then plummeted by 175.43% to -$732.0 million in 2022, then skyrocketed by 75.44% to -$179.8 million in 2023, then tumbled by 1318.55% to -$2.6 billion in 2024, then skyrocketed by 87.52% to -$318.3 million in 2025.
  • Its Net Cash Flow was -$318.3 million in Q4 2025, compared to $2.2 billion in Q3 2025 and -$225.8 million in Q2 2025.